The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Heterogeneity in early lesion changes on treatment as a marker of poor prognosis in patients (pts) with metastatic colorectal cancer (mCRC) treated with first line systemic chemotherapy ± biologic: Findings from 9,092 pts in the ARCAD database.
 
Fang-Shu Ou
No Relationships to Disclose
 
Joleen Marie Hubbard
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Genentech/Roche (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); Genentech (Inst); Merck (Inst); Senhwa Biosciences (Inst)
 
Pashtoon Murtaza Kasi
No Relationships to Disclose
 
Jesse Dixon
No Relationships to Disclose
 
Eric Van Cutsem
No Relationships to Disclose
 
Leonard Saltz
Consulting or Advisory Role - Abbvie; Lilly; McNeil PPC (I)
Research Funding - Taiho Pharmaceutical
 
Hans-Joachim Schmoll
Honoraria - Roche, GSK, Servier
Consulting or Advisory Role - Roche, Bayer, GSK
Research Funding - Roche, GSK
Travel, Accommodations, Expenses - Roche; Bayer, Servier; GSK
 
Cornelis J. A. Punt
Consulting or Advisory Role - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Richard M. Goldberg
Honoraria - Baxter; Biothera; Forty Seven; Immunocare Therapies; Immunovative Therapies; kanghong Pharma; Merck; Merrimack; Momenta Pharmaceuticals; Novo Nordisk; Pfizer; Sirtex Medical; Taiho Pharmaceutical; Targovax
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Merck (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Baxter; Merck KGaA; Sanofi
 
Paulo Hoff
No Relationships to Disclose
 
Jean-Yves Douillard
No Relationships to Disclose
 
J. Randolph Hecht
No Relationships to Disclose
 
Herbert Hurwitz
Honoraria - Genentech/Roche; Lilly/ImClone
Consulting or Advisory Role - Acceleron Pharma; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; OncoMed; TRACON Pharma
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Macrogenics (Inst); NCI (Inst); Novartis (Inst); Regeneron (Inst); TRACON Pharma (Inst)
 
Carsten Bokemeyer
Honoraria - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche; Sanofi
Consulting or Advisory Role - Bayer Schering Pharma; Hexal; Lilly/ImClone; Merck Serono; Mundipharma; Sanofi
Travel, Accommodations, Expenses - Merck Serono; Sanofi
 
Charles Fuchs
No Relationships to Disclose
 
Eduardo Diaz-Rubio
Consulting or Advisory Role - AMGEN; BAYER; GENOMICA; Merck Serono; MSD; Roche
Speakers' Bureau - MSD; SERVIER
Research Funding - AMGEN; AstraZeneca (Inst); Merck Serono (Inst); ROCHE (Inst)
 
Daniel J. Sargent
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech
Research Funding - Celgene (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Celgene
 
Aimery De Gramont
No Relationships to Disclose
 
Qian Shi
No Relationships to Disclose
 
Axel Grothey
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Eisai (Inst); Genentech/Roche (Inst); Lilly (Inst); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche